Status:
COMPLETED
Effects of Aging and Gender-Affirming Hormone Therapy on Vascular Endothelial Function and Metabolic Profiles in Transgender Women
Lead Sponsor:
University of Colorado, Denver
Collaborating Sponsors:
National Center for Advancing Translational Sciences (NCATS)
Conditions:
Transgender
Gender Identity
Eligibility:
All Genders
18-75 years
Brief Summary
This study will examine markers of vascular endothelial function (vascular health) and metabolic profiles in younger versus older transgender women (people who were assigned male at birth but whose ge...
Eligibility Criteria
Inclusion
- Aged 18-40 years old or 50-75 years old
- Identify as a transgender woman
- Have taken estradiol and spironolactone for at least one year
- Currently taking oral or transdermal estradiol
Exclusion
- Don't identify as a transgender woman
- Not currently taking estradiol or spironolactone
- Have been on estradiol and spironolactone for less than one year
- History of orchiectomy
- Current tobacco smoker
- Current illicit drug use
- History of prior or active estrogen-dependent neoplasms
- Acute liver or gallbladder disease
- Venous thromboembolism
- Hypertriglyceridemia \>500 mg/dL
- Fasted plasma glucose \>7.0 mmol/L or previously treated diabetes
- Resting blood pressure \>140/90 mmHg
Key Trial Info
Start Date :
April 17 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2023
Estimated Enrollment :
29 Patients enrolled
Trial Details
Trial ID
NCT04066283
Start Date
April 17 2019
End Date
December 31 2023
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Colorado
Aurora, Colorado, United States, 80045